“…In contrast to the study by Thomas et al (2009), in this study the ABCG2 c.421C>A polymorphism was not associated with erlotinib disposition (Rudin et al, 2008). HEK293 cells (Shukla et al, 2009), K562 cells (Kawahara et al, 2010), LLC-PK1 cells (Hu et al, 2009) MRP2 (ABCC2) Docetaxel Saos2 cells (Hu et al, 2009) MRP4 (ABCC4) PMEA Saos2 cells (Hu et al, 2009) BCRP (ABCG2) Estrone-3-sulfate (Ki = 0.32 mM), Hoechst 33342, methotrexate, pheophorbide A, rhodamine 123 HEK293 cells (Dai et al, 2009;Shukla et al, 2009), K562 cells (Kawahara et al, 2010), Saos2 cells (Hu et al, 2009), S1-M1-80 cells (Dai et al, 2009) (Li et al, 2007) c.421C>A Increased drug accumulation (ratio of trough concentrations at steady state to day 1 trough concentration; malignant solid tumours) (Li et al, 2007) c.421C>A Increased risk of diarrhea (non-small-cell lung cancer) (Cusatis et al, 2006) c.421C>A No influence on risk of skin toxicity (non-small-cell lung cancer) (Cusatis et al, 2006) c.421C>A No effect on adverse side effects for example, diarrhea, interstitial pneumonia (non-small-cell lung cancer) (Akasaka et al, 2010) -15622TT Increased risk of diarrhea (non-small-cell lung cancer) (Lemos et al, 2011) haplotype TT (c.1143C>T, -15622C>T)…”